Clinical evaluation effects of ZAX.1400.C01 in patients with coronavirus
Phase 2
- Conditions
- Incidence of inflammation due to the mechanism of COVID19.COVID-19U07.1
- Registration Number
- IRCT20210218050404N2
- Lead Sponsor
- Fasa University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Definitive diagnosis of COVID-19 disease by laboratory test from the patient's lung sputum
Age from 18 to 65 years
Patient hemoglobin saturation (SPO2) between 85% and 93%
Detection of lung involvement percentage by CT scan
20-30 breaths per minute
informed consent by participate in the study
Exclusion Criteria
liver and kidney diseases
diabetes
Pregnancy and lactation
anticoagulants administration (aspirin, Plavix, warfarin)
hypertension
History of allergies to plant products
Disagreement of the physician in charge of the patient before randomization
Inability of the patient to take oral medication
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method